Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer.

ABSTRACT:

Objective

To examine survival outcomes of women with recurrent cervical cancer who received salvage chemotherapy with modified dose-dense paclitaxel (MDDP) monotherapy (paclitaxel 80 mg/m, administered on day 1, 8, and 15 without day 22).

Materials and methods

A retrospective study was conducted to evaluate cause-specific survival after the first recurrence (SAR) of women with recurrent cervical cancer diagnosed between 2006 and 2014. Pooled analyses were performed to examine SAR in women who received MDDP monotherapy (n=17) for any treatment line, compared with those who received salvage chemotherapy with paclitaxel-doublet (n=18) and nonpaclitaxel regimens (n=52).

Results

In the whole cohort, median SAR was 13.7 months including 63 (72.4%) events. MDDP monotherapy r

SUBMITTER: Machida H 

PROVIDER: S-EPMC7528455 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature